A validated spectrofluorimetric method for the determination of nifuroxazide through coumarin formation using experimental design

Chemistry Central Journal

Asmaa Ahmed El-Zaher¹  Marianne Alphonse Mahrouse¹ 

[1] Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St, Cairo 11562, Egypt

关键词: Ethylacetoacetate;    Coumarin;    Experimental design;    Spectrofluorimetry;    Nifuroxazide;   

Others  :  787903
DOI  :  10.1186/1752-153X-7-90

 received in 2013-01-19, accepted in 2013-05-08,  发布年份 2013

【 摘 要 】

Background

Nifuroxazide (NF) is an oral nitrofuran antibiotic, having a wide range of bactericidal activity against gram positive and gram negative enteropathogenic organisms. It is formulated either in single form, as intestinal antiseptic or in combination with drotaverine (DV) for the treatment of gastroenteritis accompanied with gastrointestinal spasm. Spectrofluorimetry is a convenient and sensitive technique for pharmaceutical quality control. The new proposed spectrofluorimetric method allows its determination either in single form or in binary mixture with DV. Furthermore, experimental conditions were optimized using the new approach: Experimental design, which has many advantages over the old one, one variable at a time (OVAT approach).

Results

A novel and sensitive spectrofluorimetric method was designed and validated for the determination of NF in pharmaceutical formulation. The method was based upon the formation of a highly fluorescent coumarin compound by the reaction between NF and ethylacetoacetate (EAA) using sulfuric acid as catalyst. The fluorescence was measured at 390 nm upon excitation at 340 nm. Experimental design was used to optimize experimental conditions. Volumes of EAA and sulfuric acid, temperature and heating time were considered the critical factors to be studied in order to establish an optimum fluorescence. Each two factors were co-tried at three levels. Regression analysis revealed good correlation between fluorescence intensity and concentration over the range 20–400 ng ml^-1. The suggested method was successfully applied for the determination of NF in pure and capsule forms. The procedure was validated in terms of linearity, accuracy, precision, limit of detection and limit of quantification. The selectivity of the method was investigated by analysis of NF in presence of the co-mixed drug DV where no interference was observed. The reaction pathway was suggested and the structure of the fluorescent product was proposed. Statistical comparison between the presented method and a reported spectrophotometric one was carried out on pure and pharmaceutical formulation and revealed no significant difference.

Conclusion

The proposed method was considered economic, accurate, precise and highly sensitive. It could be easily applied in laboratory quality control for the analysis of NF in pure form and in pharmaceutical dosage form.

【 授权许可】

   
2013 El-Zaher and Mahrouse; licensee Chemistry Central Ltd.

【 图 表 】

Scheme 1

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]O’Neil MJ, Heckelman PE, Koch CB, Roman KJ, Kenny CM, D'Arecca MR: The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals. 14th edition. Whitehouse Station, NJ, USA: Merck Research laboratories Division of Merck & Co., Inc; 2006:1130.
• [2]Sweetman SC: Martindale, The Complete Drug Reference. 35th edition. London, Chicago: The Pharmaceutical Press; 2007. 274
• [3]The British Pharmacopoeia. London, UK: Her Majesty's Stationary Office; 2010:1508.
• [4]Khier AA, Elhenawee MM, Elmasry MS: Spectrophotometric method for the determination of some drugs using fast red B salt. E-J Chem 2008, 5(S2):1087-1097.
• [5]Emara KM, Refaat IH, Abdelmageed OH: HPLC and spectrophotometric determination of nifuroxazide and its pharmaceutical formulations. Egyptian J Pharm Sci 1994, 35(1–6):313-324.
• [6]Szuminska E, Cisak A: Polarographic and spectrophotometric determination of nifuroxazide in pharmaceuticals. I. Nifuroxazide determination in capsules. Acta Pol Pharm 1988, 45(6):551-558.
• [7]Szuminska E, Cisak A: Polarographic and spectrophotometric determination of nifuroxazide in pharmaceuticals. II. Determination of nifuroxazide in suspensions. Acta Pol Pharm 1990, 47(1–2):1-2.
• [8]Toral MI, Paine M, Leyton P, Richter P: Determination of attapulgite and nifuroxazide in pharmaceutical formulations by sequential digital derivative spectrophotometry. J AOAC Int 2004, 87(6):1323-1328.
• [9]Sobanska AW: Rapid determination of nifuroxazide in tablets by near-infrared spectroscopy. Chemia Analityczna (Warsaw, Poland) 2009, 54(5):1021-1033.
• [10]Berezkin VG, Onuchak LA, Evtyugina EN: Capillary thin-layer chromatography of antibacterial nitrofuran derivatives. Russ J Appl Chem 2009, 82(2):312-316.
• [11]Guinebault PR, Broquaire M, Braithwaite RA: Determination of nifuroxazide in biological fluids by automated high-performance liquid chromatography with large-volume injection. J Chromatogr 1981, 204:329-333.
• [12]Squella JA, Lemus I, Lonza G, Nunez-Vergara LJ: Electrochemical study of nifuroxazide and its analytical determination in tablets. Boletin de la Sociedad Chilena de Quimica 1991, 36(2):109-116.
• [13]Radi A, El-Laban S, Kenawy IMM: Determination of nifuroxazide in capsules by differential pulse polarography. Anal Sci 1998, 14(3):607-608.
• [14]Buchberger W, Niessner G, Bakry R: Determination of nifuroxazide with polarography and adsorptive stripping voltammetry at mercury and carbon paste electrodes. Fresenius J Anal Chem 1998, 362(2):205-208.
• [15]Sreedhar NY, Samatha KR, Reddy PRK: Electrochemical reduction behavior and analysis of nifuroxazide in formulations and urine samples. Indian Drugs 1999, 36(8):509-512.
• [16]Radi A, El Ries MA: Determination of nifuroxazide in human serum by adsorptive stripping voltammetry. Anal Sci 1999, 15(4):385-388.
• [17]Radi A: Voltammetric study of nifuroxazide at unmodified and Sephadex-modified carbon paste electrodes. Fresenius J Anal Chem 1999, 364(6):590-594.
• [18]Belal TS: A simple and sensitive spectrofluorimetric method for analysis of some nitrofuran drugs in pharmaceutical preparations. J Fluoresc 2008, 18(5):771-780.
• [19]Metwally FH, Abdelkawy M, Naguib IA: Determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by three independent analytical methods. J AOAC Int 2006, 89(1):78-87.
• [20]Ayad MM, Youssef NF, Abdellatif HE, Soliman SM: A comparative study on various spectrometries with thin layer chromatography for simultaneous analysis of drotaverine and nifuroxazide in capsules. Chem Pharm Bull 2006, 54(6):807-813.
• [21]Metwally FH: Simultaneous determination of Nifuroxazide and Drotaverine hydrochloride in pharmaceutical preparations by bivariate and multivariate spectral analysis. Spectrochim Acta A Mol Biomol Spectrosc 2008, 69A(2):343-349.
• [22]Azhlwar S, Ravi TK: Stability indicating HPLC method for simultaneous determination of drotaverine and aceclofenac. Int J Pharm Pharm Sci 2011, 3(1):245-250.
• [23]Leardi R: Experimental design in chemistry: A tutorial. Anal Chim Acta 2009, 652:161-172.
• [24]Miller JN, Miller JC: Statistics and Chemometrics for Analytical Chemistry. 6th edition. England: Pearson education Limited; 2010:186-216.
• [25]Khamanga SM, Walker RB: The use of experimental design in the development of an HPLC-ECD method for the analysis of captopril. Talanta 2011, 83:1037-1049.
• [26]Boussac N, Galmier MJ, Dauphin G, Madesclaire M, Lartigue C: Nifuroxazide photodecomposition: Identification of the (Z)-isomer by 1H-NMR Study. Mikrochim Acta 2003, 141(3–4):179-181.
• [27]Deming SN, Morgan SL: Experimental Design: A Chemometric Approach. 2nd edition. Amsterdam, London, New York, Tokyo: Elsevier Publishers; 1993:227-274. 151–169
• [28]Montgomery DC: Design and Analysis of Experiments. 7th edition. Asia: John Wiley & Sons, Inc; 2009:207-263. 1–22, 60–114
• [29]Q2 (R1) Validation of analytical procedures, Proceedings of the International Conference on Harmonisation (ICH). Geneva: Commission of the European Communities; 2005.
• [30]Patnaik P: Dean’s Analytical Chemistry Handbook. 2nd edition. New York, London, Toronto: McGraw-Hill; 2004:648.
• [31]Kellner R, Mermet JM, Otto M, Valcárcel M, Widmer HM: Analytical Chemistry. Weinheim: Wiley-VCH Verlay GmbH & Co. KGaA; 2004. 746
• [32]Skoog DA, West DM, Holler FJ, Crouch SR: Fundamentals of Analytical Chemistry. 8th edition. Australia, United States: Brooks/Cole, a division of Thomson learning, Inc; 2004:825.
• [33]Cagigal E, González L, Alonso RM, Jiménez RM: Experimental design methodologies to optimize the spectrofluorimetric determination of losartan and valsartan in human urine. Talanta 2001, 54:1121-1133.
• [34]Srinubabu G, Raju CAI, Sarath N, Kumar PK, Rao JVLNS: Development and validation of a HPLC method for the determination of voriconazole in pharmaceutical formulation using an experimental design. Talanta 2007, 71:1424-1429.
• [35]Awotwe-Otoo D, Agarabi C, Faustino PJ, Habib MJ, Lee S, Khan MA, Shah RB: Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate. J Pharm Biomed Anal 2012, 62:61-67.
• [36]Belal F, Al-Shaboury S, Al-Tamrah AS: Spectrophotometric determination of labetolol in pharmaceutical preparations and spiked human urine through the formation of coumarin derivative. J Pharm Biomed Anal 2002, 30:1191-1196.